Education
In 1972, following the receipt of her Doctor of Philosophy, Wong-Staal undertook postdoctoral research at University of California, San Diego.
黃以靜
In 1972, following the receipt of her Doctor of Philosophy, Wong-Staal undertook postdoctoral research at University of California, San Diego.
She was the first scientist to clone Human Immunodeficiency Virus and determine the function of its genes, a major step in proving that Human Immunodeficiency Virus is the cause of Acquired Immune Deficiency Syndrome. From 1990 to 2002, she held the Florence Riford Chair in Acquired Immune Deficiency Syndrome Research at the University of California at San Diego (University of California, San Diego). Her postdoctoral work continued under 1974, when she left to work for Robert Gallo at the National Cancer Institute (National Cancer Institute). At the institute, Wong-Staal began her research into retroviruses.
In 1983, Wong-Staal, Gallo and her team of National Cancer Institute scientists identified Human Immunodeficiency Virus as the cause of Acquired Immune Deficiency Syndrome, simultaneously with Luc Montagnier.
Two years later, Wong-Staal cloned Human Immunodeficiency Virus and then completed genetic mapping of the virus. The genetic mapping made it possible to develop Human Immunodeficiency Virus tests.
In 1990, Wong-Staal moved from National Cancer Institute to University of California, San Diego. Wong-Staal continued her research into Human Immunodeficiency Virus and Acquired Immune Deficiency Syndrome at University of California, San Diego. In 1994 she was named as chairman of University of California, San Diego"s newly created Center for Acquired Immune Deficiency Syndrome Research. In that same year, Wong-Staal was elected to the Institute of Medicine of the United States. National Academies.
In the 1990s, Wong-Staal"s research focused on gene therapy, using a ribozyme "molecular knife" to repress Human Immunodeficiency Virus in stem cells.
The protocol she developed was the second to be funded by the United States government. In 2002, Wong-Staal retired from University of California, San Diego and now holds the title of Professor Emerita. She then joined Immusol, a biopharmaceutical company that she co-founded while she was at University of California, San Diego, as Chief Scientific Officer.
Recognizing the need for improved drugs for hepatitis C (HCV), she transitioned Immusol to an HCV therapeutics focus and renamed it iTherX Pharmaceuticals to reflect this.
That same year, Discover named Wong-Staal one of the fifty most extraordinary women scientists. Wong-Staal remains as a Research Professor of Medicine at University of California, San Diego. In 2007, The Daily Telegraph heralded Doctor Wong-Staal as #32 of the "Top 100 Living Geniuses.".
